New Zealand’s Pharmaceutical Management Agency PHARMAC has approved proposals for funding Pfizer’s (NYSE: PFE) sildenafil (trade name Revatio for Raynaud’s and PAH and the active ingredient of erectile dysfunction drug Viagra) for Raynaud’s phenomenon from March 1, 2013 and bosentan, Swiss biotech firm Actelion’s (SIX: ATLN) Tracleer, as a first-line treatment option for children with idiopathic pulmonary arterial hypertension (PAH) or pulmonary hypertension secondary to congenital heart disease from 1 February 2013.
Sildenafil for Raynaud’s phenomenon
From March 1, sildenafil will be subject to the following Special Authority restrictions:
Initial application – (Raynaud’s phenomenon) from any relevant practitioner. Approvals valid without further renewal unless notified for patients meeting the following criteria:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze